Journal: Frontiers in Immunology

Article Title: Nanomaterials for liver cancer targeting: research progress and future prospects

doi: 10.3389/fimmu.2025.1496498

Figure Lengend Snippet: Comparison of the characteristics and properties of several common nanomaterials.

Article Snippet: NPSC , Platinum nanoparticles , Bmi-1 is an oncogene that promotes malignancy in various cancers, including hepatocellular carcinoma (HCC). Chemotherapeutic agents, such as cisplatin (CDDP), can treat malignant tumors by targeting Bmi-1. However, CDDP treatment can paradoxically lead to elevated Bmi-1 levels, contributing to the development of HCC resistance. To address this issue, the authors of this paper synthesized a nanocarrier complex, termed NPSC, which comprises siRNA, a platinum nanocore, and calcium phosphate (CaP). This NPSC complex is designed to transport both CDDP and siRNA, thereby enhancing the therapeutic efficacy against HCC. The siRNA component of the NPSC complex increases the sensitivity of cancer cells to CDDP by silencing the Bmi-1 gene, while the platinum nanocore facilitates the delivery of CDDP. The NPSC complex was found to inhibit cancer cell proliferation and improve drug utilization compared to the administration of free CDDP. Additionally, the authors proposed two strategies to combat drug resistance: silencing the Bmi-1 gene and using lipid-calcium-phosphate (LCP) nanocarriers for drug delivery. These findings suggest that the NPSC complex could be a promising approach to overcoming chemoresistance in HCC by targeting Bmi-1. , ( ) .

Techniques: Comparison, Adsorption, In Vitro, Dispersion, Activity Assay

Journal: Frontiers in Immunology

Article Title: Nanomaterials for liver cancer targeting: research progress and future prospects

doi: 10.3389/fimmu.2025.1496498

Figure Lengend Snippet: Existing studies of nanomaterials used as carriers to deliver sorafenib.

Article Snippet: NPSC , Platinum nanoparticles , Bmi-1 is an oncogene that promotes malignancy in various cancers, including hepatocellular carcinoma (HCC). Chemotherapeutic agents, such as cisplatin (CDDP), can treat malignant tumors by targeting Bmi-1. However, CDDP treatment can paradoxically lead to elevated Bmi-1 levels, contributing to the development of HCC resistance. To address this issue, the authors of this paper synthesized a nanocarrier complex, termed NPSC, which comprises siRNA, a platinum nanocore, and calcium phosphate (CaP). This NPSC complex is designed to transport both CDDP and siRNA, thereby enhancing the therapeutic efficacy against HCC. The siRNA component of the NPSC complex increases the sensitivity of cancer cells to CDDP by silencing the Bmi-1 gene, while the platinum nanocore facilitates the delivery of CDDP. The NPSC complex was found to inhibit cancer cell proliferation and improve drug utilization compared to the administration of free CDDP. Additionally, the authors proposed two strategies to combat drug resistance: silencing the Bmi-1 gene and using lipid-calcium-phosphate (LCP) nanocarriers for drug delivery. These findings suggest that the NPSC complex could be a promising approach to overcoming chemoresistance in HCC by targeting Bmi-1. , ( ) .

Techniques: Activity Assay, Preserving, In Vitro, Activation Assay, Concentration Assay, Staining, Expressing, Inhibition, In Vivo, Residue, Binding Assay, Polymer, Solubility

Journal: Frontiers in Immunology

Article Title: Nanomaterials for liver cancer targeting: research progress and future prospects

doi: 10.3389/fimmu.2025.1496498

Figure Lengend Snippet: The rest of the nanomaterials in liver cancer.

Article Snippet: NPSC , Platinum nanoparticles , Bmi-1 is an oncogene that promotes malignancy in various cancers, including hepatocellular carcinoma (HCC). Chemotherapeutic agents, such as cisplatin (CDDP), can treat malignant tumors by targeting Bmi-1. However, CDDP treatment can paradoxically lead to elevated Bmi-1 levels, contributing to the development of HCC resistance. To address this issue, the authors of this paper synthesized a nanocarrier complex, termed NPSC, which comprises siRNA, a platinum nanocore, and calcium phosphate (CaP). This NPSC complex is designed to transport both CDDP and siRNA, thereby enhancing the therapeutic efficacy against HCC. The siRNA component of the NPSC complex increases the sensitivity of cancer cells to CDDP by silencing the Bmi-1 gene, while the platinum nanocore facilitates the delivery of CDDP. The NPSC complex was found to inhibit cancer cell proliferation and improve drug utilization compared to the administration of free CDDP. Additionally, the authors proposed two strategies to combat drug resistance: silencing the Bmi-1 gene and using lipid-calcium-phosphate (LCP) nanocarriers for drug delivery. These findings suggest that the NPSC complex could be a promising approach to overcoming chemoresistance in HCC by targeting Bmi-1. , ( ) .

Techniques: Expressing, Synthesized, Drug discovery, Binding Assay, Liposomes, Permeability, Activation Assay, Solubility, In Vivo, Blocking Assay